← Apogee Enterprises overview

Apogee Enterprises vs Everjoy Health: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Apogee Enterprises Inc (APOG)

Q3 2026
▲3

Apogee's Q2 Beat and Raised Guidance Reframe a Weak Year

  • Q2 results blow past low expectations, guidance raised Apogee reported Q2 sales up 9.2% to $391.1 million and adjusted EPS up 19.4% to $1.17, then raised full-year EPS guidance to $3.00-$3.40 and sales to $1.46-$1.50 billion. This directly lifts the earnings outlook that drives the stock.

    The quarter's beat and raised guidance are the main new force behind APOG's value.

  • Kalwall acquisition adds real sales and margin A $16.4 million contribution from the Kalwall acquisition, plus price and favorable mix, drove the sales gain, while operating margin widened to 8.6%. Buying growth is helping APOG offset lower volume in its core business.

    It explains the source of the sales and margin improvement that supports the raised outlook.

  • GroGlass deal adds higher-margin coating technology Apogee agreed to buy Latvia-based GroGlass for up to €62.5 million, adding anti-reflective coating capabilities expected to bring about $30 million in first-year revenue at roughly 25% EBITDA margin, well above the segment's 14.8%. It is a long-term growth bet, but execution risk remains.

    The acquisition is a new strategic move that could improve future profitability and growth.

  • Earnings estimates had already been rising before the report In mid-July, Apogee's current-year earnings consensus estimate had risen 7.1% over 60 days, earning a Strong Buy rating. That improving analyst sentiment set the stage for the Q2 beat, but it is a backward-looking signal now confirmed by actual results.

    It shows the pre-existing trend in estimates that the Q2 report later validated.

August 2026
▲3

Apogee's Q2 Beat and Raised Guidance Reframe a Weak Year

  • Q2 results blow past low expectations, guidance raised Apogee reported Q2 sales up 9.2% to $391.1 million and adjusted EPS up 19.4% to $1.17, then raised full-year EPS guidance to $3.00-$3.40 and sales to $1.46-$1.50 billion. This directly lifts the earnings outlook that drives the stock.

    The quarter's beat and raised guidance are the main new force behind APOG's value.

  • Kalwall acquisition adds real sales and margin A $16.4 million contribution from the Kalwall acquisition, plus price and favorable mix, drove the sales gain, while operating margin widened to 8.6%. Buying growth is helping APOG offset lower volume in its core business.

    It explains the source of the sales and margin improvement that supports the raised outlook.

  • GroGlass deal adds higher-margin coating technology Apogee agreed to buy Latvia-based GroGlass for up to €62.5 million, adding anti-reflective coating capabilities expected to bring about $30 million in first-year revenue at roughly 25% EBITDA margin, well above the segment's 14.8%. It is a long-term growth bet, but execution risk remains.

    The acquisition is a new strategic move that could improve future profitability and growth.

  • Earnings estimates had already been rising before the report In mid-July, Apogee's current-year earnings consensus estimate had risen 7.1% over 60 days, earning a Strong Buy rating. That improving analyst sentiment set the stage for the Q2 beat, but it is a backward-looking signal now confirmed by actual results.

    It shows the pre-existing trend in estimates that the Q2 report later validated.

Latest
▲3

Apogee's Q2 Beat and Raised Guidance Reframe a Weak Year

  • Q2 results blow past low expectations, guidance raised Apogee reported Q2 sales up 9.2% to $391.1 million and adjusted EPS up 19.4% to $1.17, then raised full-year EPS guidance to $3.00-$3.40 and sales to $1.46-$1.50 billion. This directly lifts the earnings outlook that drives the stock.

    The quarter's beat and raised guidance are the main new force behind APOG's value.

  • Kalwall acquisition adds real sales and margin A $16.4 million contribution from the Kalwall acquisition, plus price and favorable mix, drove the sales gain, while operating margin widened to 8.6%. Buying growth is helping APOG offset lower volume in its core business.

    It explains the source of the sales and margin improvement that supports the raised outlook.

  • GroGlass deal adds higher-margin coating technology Apogee agreed to buy Latvia-based GroGlass for up to €62.5 million, adding anti-reflective coating capabilities expected to bring about $30 million in first-year revenue at roughly 25% EBITDA margin, well above the segment's 14.8%. It is a long-term growth bet, but execution risk remains.

    The acquisition is a new strategic move that could improve future profitability and growth.

  • Earnings estimates had already been rising before the report In mid-July, Apogee's current-year earnings consensus estimate had risen 7.1% over 60 days, earning a Strong Buy rating. That improving analyst sentiment set the stage for the Q2 beat, but it is a backward-looking signal now confirmed by actual results.

    It shows the pre-existing trend in estimates that the Q2 report later validated.

Everjoy Health Group Co Ltd (002162.CS)